SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-037119
Filing Date
2021-03-16
Accepted
2021-03-16 16:10:13
Documents
2
Period of Report
2021-03-12

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm219640-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm219640-1_3seq1.xml 3 1589
2 EXHIBIT 24.1 tm219640d1_ex24-1.htm EX-24.1 7143
  Complete submission text file 0001104659-21-037119.txt   10320
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NABRIVA THERAPEUTICS PLC 1000 CONTINENTAL DRIVE, SUITE 600 KING OF PRUSSIA PA 19406
Business Address
Dolan Daniel (Reporting) CIK: 0001826818 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37558 | Film No.: 21745784